Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 8/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326172 | 0.80 | SYK (0.39) | HDAC4HDAC6SYKCCR1TAS1R3 | |
| SCHEMBL29326175 | 0.77 | SYK (0.40) | HDAC4HDAC6SYKGAA | |
| SCHEMBL6922118 | 0.77 | MCHR1 (0.43) | HDAC4HDAC6SYKBTKGAA | |
| SCHEMBL12885089 | 0.76 | BTK (0.53) | HDAC4HDAC6BTKGAAEPHX1 | |
| SCHEMBL19773841 | 0.76 | BTK (0.53) | HDAC4HDAC6BTKGAAEPHX1 | |
| SCHEMBL765253 | 0.76 | BTK (0.53) | HDAC4HDAC6BTKGAAEPHX1 | |
| SCHEMBL29155930 | 0.75 | IDH1 (0.45) | SYKPTPN11 | |
| SCHEMBL29325890 | 0.75 | IDH1 (0.45) | SYKPTPN11 | |
| SCHEMBL29325892 | 0.75 | IDH1 (0.45) | SYKPTPN11 | |
| SCHEMBL31341803 | 0.75 | IDH1 (0.45) | SYKPTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4345097-A1 | SUBSTITUTED TRIAZINE COMPOUND | Astellas Pharma Inc. (JP) | 2024-04-03 | — | — | EP | disclosed |
| WO-2022230912-A1 | SUBSTITUTED TRIAZINE COMPOUND | アステラス製薬株式会社 | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | HDAC4 411/4885HDAC6 393/4885SYK 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.